The Joint Partners Forum for strengthening and aligning TB diagnosis and treatment, which will unite GLI and GDI partners, will be convened at World Health Organization Headquarters, Geneva, Switzerland on April 27-30, 2015.

The 9th meeting on HIV/TB research in conjunction with CROI 2015 was organised by the World Health Organisation (WHO) in Seattle, USA on February 23, 2015. The meeting was convened by Haileyesus Getahun and Meg Doherty of WHO and chaired by Richard Chaisson of John Hopkins University and Constance Benson of University of California, San Diego. The meeting was opened with remarks from Eric Goosby, the UN Special Envoy on Tuberculosis, who briefly shared his plans to support the advancement of TB research which is now included as one of the three pillars of the WHO’s new End TB Strategy.

23 February 2015 | Geneva - Use of the same syringe or needle to give injections to more than one person is driving the spread of a number of deadly infectious diseases worldwide. Millions of people could be protected from infections acquired through unsafe injections if all health-care programmes switched to syringes that cannot be used more than once. For these reasons, the World Health Organization (WHO) is launching a new policy on injection safety and a global campaign with support from the IKEA Foundation and Gavi, the Vaccine Alliance, to help all countries tackle the pervasive issue of unsafe injections.

The deadline for the submission of public comments on applications to be considered by the 20th Expert Committee on the Selection and Use of Essential medicines has been extended until Wednesday 25 February 2015.

23 Februrary 2015, 11:30-13:30 | Sheraton Seattle Hotel, 1400 Sixth Avenue, Seattle, WA 98101, USA

Technical and operational ‘how-to’: practical considerations

For the first time, the World Health Organization has issued guidelines on testing, treating and managing latent TB infection in individuals with high risk of developing disease.

The guidance lists five conditions that must be in place if delamanid is used to treat adults with MDR-TB.

WHO’s "Global Tuberculosis Report 2014" shows that 9 million people developed TB in 2013, and 1.5 million died, including 360 000 people who were HIV positive.

Report of a consensus meeting convened by the Global TB Programme of the World Health Organization.